Moreover, alpinetin strongly moderated abnormal lipids metabolism in NAFLD by decreasing thioredoxin-interacting protein (TXNIP)/xanthine oxidase (XO), Stearoyl-CoA desaturase1 (SCD1), and fatty acid synthase (FAS) expression levels (Zhou et al., 2018). The gene discussed is TXNIP; the disease is metabolic dysfunction-associated steatotic liver disease.